molsidomine has been researched along with Body Weight in 12 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 7.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 7.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| "The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats." | 3.73 | Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. ( Andersen, CU; Mulvany, MJ; Simonsen, U, 2005) |
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 3.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| " We investigated whether a NO-donor, molsidomine, administered during NO synthase inhibition, could restore a normal pregnancy." | 3.69 | Lack of beneficial effects on the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats. ( Boulanger, H; Es-Slami, S; Giudicelli, JF; Richer, C, 1996) |
| "Treatment with molsidomine (1 mg/kg/day) during cholesterol withdrawal did not affect plaque size but increased the thickness of the subendothelial macrophage-free layer consisting of SMC, and normalized both superoxide production and ecSOD mRNA expression." | 1.32 | Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability during cholesterol lowering in rabbits. ( Bult, H; De Cleen, DM; De Meyer, GR; Herman, AG; Knaapen, MW; Kockx, MM; Martinet, W, 2003) |
| "We studied the effects of long-term administration of molsidomine and pentaerythrityl tetranitrate (PETN) on the cardiovascular system of spontaneously hypertensive rats (SHR)." | 1.32 | Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats. ( Fáberová, V; Kristek, F; Varga, I, 2003) |
| "4." | 1.32 | The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. ( de Dam, MY; Elmedal, B; Mulvany, MJ; Simonsen, U, 2004) |
| " Here, we evaluated whether chronic administration of an NO donor, molsidomine, controlled systemic blood pressure and renal disease progression and prolonged survival in rats with renal mass reduction (RMR)." | 1.30 | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. ( Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Meyer, GR | 2 |
| Kockx, MM | 1 |
| Knaapen, MW | 1 |
| Martinet, W | 1 |
| De Cleen, DM | 1 |
| Bult, H | 2 |
| Herman, AG | 2 |
| Peters, H | 1 |
| Daig, U | 1 |
| Martini, S | 1 |
| Rückert, M | 1 |
| Schäper, F | 1 |
| Liefeldt, L | 1 |
| Krämer, S | 1 |
| Neumayer, HH | 1 |
| Cukiernik, M | 1 |
| Mukherjee, S | 1 |
| Downey, D | 1 |
| Chakabarti, S | 1 |
| Kristek, F | 1 |
| Fáberová, V | 1 |
| Varga, I | 1 |
| Elmedal, B | 1 |
| de Dam, MY | 1 |
| Mulvany, MJ | 2 |
| Simonsen, U | 2 |
| Andersen, CU | 1 |
| Joly, GA | 1 |
| Schini, VB | 1 |
| Hughes, H | 1 |
| Vanhoutte, PM | 1 |
| Böger, RH | 1 |
| Bode-Böger, SM | 1 |
| Gerecke, U | 1 |
| Frölich, JC | 1 |
| Richer, C | 1 |
| Boulanger, H | 1 |
| Es-Slami, S | 1 |
| Giudicelli, JF | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Noris, M | 1 |
| Corna, D | 1 |
| Benedetti, G | 1 |
| Bruzzi, I | 1 |
| Todeschini, M | 1 |
| Remuzzi, G | 1 |
| Attia, DM | 1 |
| Ni, ZN | 1 |
| Boer, P | 1 |
| Attia, MA | 1 |
| Goldschmeding, R | 1 |
| Koomans, HA | 1 |
| Vaziri, ND | 1 |
| Joles, JA | 1 |
12 other studies available for molsidomine and Body Weight
| Article | Year |
|---|---|
Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability during cholesterol lowering in rabbits.
Topics: Acetonitriles; Animals; Aorta; Apoptosis; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, D | 2003 |
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Enzyme Inhibitors; Fibronectins; Fibrosis; Gene Expr | 2003 |
Heme oxygenase in the retina in diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothel | 2003 |
Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats.
Topics: Animals; Aorta; Aorta, Thoracic; Blood Platelets; Blood Pressure; Body Weight; Cardiovascular System | 2003 |
The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Administration, O | 2004 |
Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Topics: Acetylcholine; Actins; Animals; Atrial Natriuretic Factor; Body Weight; Dose-Response Relationship, | 2005 |
Influence of chronic treatment with a nitric oxide donor on fatty streak development and reactivity of the rabbit aorta.
Topics: Acetylcholine; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Body Weight; Cholesterol; Dietary | 1995 |
Potentiation of the hyporeactivity induced by in vivo endothelial injury in the rat carotid artery by chronic treatment with fish oil.
Topics: Analysis of Variance; Animals; Arginine; Blood Pressure; Body Weight; Carotid Arteries; Carotid Arte | 1995 |
Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Cholesterol; Chromatography, Gas; Cyclic GMP; Heart; | 1994 |
Lack of beneficial effects on the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats.
Topics: Animals; Blood Pressure; Body Weight; Enzyme Inhibitors; Female; Fetus; Heart; Heart Rate; Molsidomi | 1996 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease | 1999 |
Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats.
Topics: Animals; Blood Pressure; Body Weight; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Chol | 2002 |